The role of duloxetine in the treatment of anxiety disorders

Domenico De Berardis1,2,3, Nicola Serroni2, Alessandro Carano1,4, Marco Scali1,4, Alessandro Valchera5, Daniela Campanella1,2, Alessandro D&rsquo;Albenzio1, Berardo Di Giuseppe2, Francesco Saverio Moschetta2, Rosa Maria Salerno1, Filippo Maria Ferro11Department of Oncology and Neurosciences,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Domenico De Berardis, Nicola Serroni, Alessandro Carano, Marco Scali, Alessandro Valchera, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a5df458efc8343dda82baca21994ae6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5df458efc8343dda82baca21994ae6f
record_format	dspace
spelling	oai:doaj.org-article:a5df458efc8343dda82baca21994ae6f2021-12-02T04:08:07ZThe role of duloxetine in the treatment of anxiety disorders1176-63281178-2021https://doaj.org/article/a5df458efc8343dda82baca21994ae6f2008-07-01T00:00:00Zhttp://www.dovepress.com/the-role-of-duloxetine-in-the-treatment-of-anxiety-disorders-a1861https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Domenico De Berardis1,2,3, Nicola Serroni2, Alessandro Carano1,4, Marco Scali1,4, Alessandro Valchera5, Daniela Campanella1,2, Alessandro D&rsquo;Albenzio1, Berardo Di Giuseppe2, Francesco Saverio Moschetta2, Rosa Maria Salerno1, Filippo Maria Ferro11Department of Oncology and Neurosciences, Institute of Psychiatry, &ldquo;G. D&rsquo;Annunzio&rdquo; University of Chieti, Italy; 2National Health Service, Department of Mental Health, SPDC Teramo, Italy; 3ITAB, Institute for Advanced Biomedical Technologies, &ldquo;G. D&rsquo;Annunzio&rdquo; University Foundation, Chieti, Italy; 4National Health Service, Department of Mental Health, ASUR Marche 8, Civitanova Marche, Italy; 5Division of Psychiatry, &ldquo;S. Giuseppe&rdquo; Clinic, Ascoli Piceno, ItalyAbstract: Anxiety disorders (ADs) are the most common type of psychiatric disorders, with a mean incidence of 18.1% and a lifetime prevalence of 28.8%. Pharmacologic options studied for treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic drug (NaSSA) and dual-reuptake inhibitors of serotonin and norepinephrine (SNRIs). In this context, the development of SNRIs (venlafaxine and duloxetine) has been particularly useful. As a dual-acting intervention that targets two neurotransmitter systems, these medications would appePar promising for the treatment of ADs. The purpose of this review was to elucidate current facts and views about the role of duloxetine in the treatment of ADs. In February 2007, duloxetine was approved by FDA for the treatment of generalized anxiety disorder (GAD). The results of trials evaluating the use duloxetine in the treatment of GAD are supportive on its efficacy even if further studies on long-term use are needed. Apart from some interesting case reports, no large studies are, to date, present in literature about duloxetine and other ADs such as panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Therefore, the clinical efficacy and the relative good tolerability of duloxetine may be further investigated to widen the therapeutic spectrum of ADs.Keywords: anxiety disorders, duloxetine, serotonin, noradrenaline, efficacy, tolerability Domenico De BerardisNicola SerroniAlessandro CaranoMarco ScaliAlessandro Valcheraet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 929-935 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Domenico De Berardis Nicola Serroni Alessandro Carano Marco Scali Alessandro Valchera et al The role of duloxetine in the treatment of anxiety disorders
description	Domenico De Berardis1,2,3, Nicola Serroni2, Alessandro Carano1,4, Marco Scali1,4, Alessandro Valchera5, Daniela Campanella1,2, Alessandro D&rsquo;Albenzio1, Berardo Di Giuseppe2, Francesco Saverio Moschetta2, Rosa Maria Salerno1, Filippo Maria Ferro11Department of Oncology and Neurosciences, Institute of Psychiatry, &ldquo;G. D&rsquo;Annunzio&rdquo; University of Chieti, Italy; 2National Health Service, Department of Mental Health, SPDC Teramo, Italy; 3ITAB, Institute for Advanced Biomedical Technologies, &ldquo;G. D&rsquo;Annunzio&rdquo; University Foundation, Chieti, Italy; 4National Health Service, Department of Mental Health, ASUR Marche 8, Civitanova Marche, Italy; 5Division of Psychiatry, &ldquo;S. Giuseppe&rdquo; Clinic, Ascoli Piceno, ItalyAbstract: Anxiety disorders (ADs) are the most common type of psychiatric disorders, with a mean incidence of 18.1% and a lifetime prevalence of 28.8%. Pharmacologic options studied for treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic drug (NaSSA) and dual-reuptake inhibitors of serotonin and norepinephrine (SNRIs). In this context, the development of SNRIs (venlafaxine and duloxetine) has been particularly useful. As a dual-acting intervention that targets two neurotransmitter systems, these medications would appePar promising for the treatment of ADs. The purpose of this review was to elucidate current facts and views about the role of duloxetine in the treatment of ADs. In February 2007, duloxetine was approved by FDA for the treatment of generalized anxiety disorder (GAD). The results of trials evaluating the use duloxetine in the treatment of GAD are supportive on its efficacy even if further studies on long-term use are needed. Apart from some interesting case reports, no large studies are, to date, present in literature about duloxetine and other ADs such as panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Therefore, the clinical efficacy and the relative good tolerability of duloxetine may be further investigated to widen the therapeutic spectrum of ADs.Keywords: anxiety disorders, duloxetine, serotonin, noradrenaline, efficacy, tolerability
format	article
author	Domenico De Berardis Nicola Serroni Alessandro Carano Marco Scali Alessandro Valchera et al
author_facet	Domenico De Berardis Nicola Serroni Alessandro Carano Marco Scali Alessandro Valchera et al
author_sort	Domenico De Berardis
title	The role of duloxetine in the treatment of anxiety disorders
title_short	The role of duloxetine in the treatment of anxiety disorders
title_full	The role of duloxetine in the treatment of anxiety disorders
title_fullStr	The role of duloxetine in the treatment of anxiety disorders
title_full_unstemmed	The role of duloxetine in the treatment of anxiety disorders
title_sort	role of duloxetine in the treatment of anxiety disorders
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/a5df458efc8343dda82baca21994ae6f
work_keys_str_mv	AT domenicodeberardis theroleofduloxetineinthetreatmentofanxietydisorders AT nicolaserroni theroleofduloxetineinthetreatmentofanxietydisorders AT alessandrocarano theroleofduloxetineinthetreatmentofanxietydisorders AT marcoscali theroleofduloxetineinthetreatmentofanxietydisorders AT alessandrovalchera theroleofduloxetineinthetreatmentofanxietydisorders AT etal theroleofduloxetineinthetreatmentofanxietydisorders AT domenicodeberardis roleofduloxetineinthetreatmentofanxietydisorders AT nicolaserroni roleofduloxetineinthetreatmentofanxietydisorders AT alessandrocarano roleofduloxetineinthetreatmentofanxietydisorders AT marcoscali roleofduloxetineinthetreatmentofanxietydisorders AT alessandrovalchera roleofduloxetineinthetreatmentofanxietydisorders AT etal roleofduloxetineinthetreatmentofanxietydisorders
_version_	1718401450291232768

The role of duloxetine in the treatment of anxiety disorders

Ejemplares similares